BCG和细胞因子治疗非肌层浸润性膀胱癌的研究进展
摘要
膀胱恶性肿瘤是泌尿系统最常见的肿瘤,世界范围内其年龄标准化（ASR）发生率在男性和女性分别为10.1/10万、2.5/10万[1]。在我国,2002年膀胱癌ASR发病率男性为3.8/10万,女性为1.4/10万[2]。其中75%～85%的膀胱癌局限于黏膜（CIS）或黏膜下层（Ta、T1）,
出处
《现代泌尿生殖肿瘤杂志》
2011年第5期309-311,共3页
Journal of Contemporary Urologic and Reproductive Oncology
参考文献22
-
1Ploeg M, Aben IKK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world[J]. World J Urol,2009,27(3):289-293.
-
2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA CancerJ C1in,2005,55(2):74-108.
-
3Babjuk M, Oosterlinck W, Sylvester R, et al. EAU Guidelines on non-muscle invasive urothelial carcinoma of the blad der, the 2011 update[J]. Eur Urol,2011,59(6):997-1008.
-
4Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, Tl, and Tis):2007 update[J]. J Urol,2007,178(6): 2314-2330.
-
5Morales A, Eidinger D, Bruce AW. lntracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors[J]. J Uro1,1976,116(2):180-183.
-
6Suttmann H, Riemensberger J, Bentien C, et al. Neutrophi granulocytes are required for effective Bacillus Calmette-Guer in inamunotherapy of bladder cancer and orchestrate local im mune responses[J]. Cancer Res,2006,66(16):8250-8257.
-
7Takeuchi A, Dejima T, Yamada H, ct al. IL 17 production by gammadeha T cells is important for the antitumor effect of Mycobacterium bovis bacillus Galmette-Guerin treatment against bladder cancer[J]. Eur J Immunol,2011,41(l):246-251.
-
8Luo Y, Han R, Evanoff DP, et al. lnterleukin-10 inhibits Mycobacterium bovis bacillus Calmette Guerin (BCG)in duced macrophage cytotoxicity against bladder cancer cells[J]. ClinExplmmunol,2010,160(3):359-368.
-
9Andrade PM, Chade DC, Borra RC, et al. The therapeutic potential of recombinant BCGexpressing the antigen S1PTin the intravesical treatment of bladder cancer[J]. Urol Oncol, 2010,28(5):520-525.
-
10Shelley MD, Kynaston H, Court J, et al. A systematic re view of intravesical Bacillus Calmette Guerin plus transure thral resection vs transurethral resection alone in Ta and T bladder cancer[J]. BJU Int,2001,88(3) :209-216.
-
1杨俊兰.细胞因子治疗实体瘤的现状[J].解放军医学情报,1994,8(4):178-179.
-
2黄俊祥.转移性肾癌的诊治进展[J].大家健康（学术版）,2013(3):68-69. 被引量：1
-
3高德宗,孙靖中.Fas系统与肿瘤治疗[J].国外医学（肿瘤学分册）,2005,32(5):368-371. 被引量：7
-
4彭俊杰,蔡三军.大肠癌的生物治疗进展[J].标记免疫分析与临床,2005,12(1):46-49.
-
5王薇.头颈肿瘤细胞因子治疗现状与展望[J].国外医学（耳鼻咽喉科学分册）,2000,24(1):20-23. 被引量：2
-
6肖正达,金冠球,谢宇野,林向阳,徐瑾.内镜下注细胞因子治疗晚期胃癌[J].中华消化内镜杂志,1997,14(1):38-39.
-
7王德斌.癌生物治疗进展[J].高科技与产业化,2000,6(3):15-19.
-
8郑航,李长建,李军,靳全恒,窦启锋.后腹腔镜下肾部分切除术联合过继免疫疗法应用于肾癌的疗效分析[J].湖南师范大学学报（医学版）,2016,13(4):95-97. 被引量：4
-
9杨华,王华庆.肾透明细胞癌的全身治疗现状及进展[J].国外医学（外科学分册）,2005,32(6):449-453.
-
10单婵婵,吴昌平,蒋敬庭.抗肿瘤细胞免疫治疗肿瘤患者的疗效评价[J].现代肿瘤医学,2013,21(8):1882-1884. 被引量：4
